新聞Dmedglobal receives financing of $100M in Series C.dMed, a Shangai, China-based clinical CRO, completed a US$100m Series C financing.
新聞Dmedglobal acquired Target Health, Inc. on Jan 1st '19.In 2019, dMed completed the acquisition of Target Health, a full-service New York-based CRO, to further extend its global footprint and service offerings.
新聞Dmedglobal partners with NMS Group.dMed has entered a strategic collaboration with NMS Group at early stage of the project, providing a customized and integrated clinical development services for NMS Group to enter the Chinese market, and delivering high-quality results to accelerate the clinical trials process.
